Clinical Trial: Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Evaluation of the Onset and Duration of Action of R89674 0.25% Ophthalmic Solution in Conjunctival Allergen Challenge (CAC) Model of Acut
Brief Summary: The purpose of this study is to establish the efficacy of R89674 0.25% ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allergic conjunctivitis
Detailed Summary:
Sponsor: Vistakon Pharmaceuticals
Current Primary Outcome: Ocular itching and conjunctival redness post challenge
Original Primary Outcome: Same as current
Current Secondary Outcome: Ciliary and episcieral redness; chemosis; lid swelling; tearing; ocular mucous discharge; and nasal symptoms. All measured postchallenge
Original Secondary Outcome: Same as current
Information By: Vistakon Pharmaceuticals
Dates:
Date Received: October 14, 2005
Date Started: October 2005
Date Completion:
Last Updated: September 26, 2011
Last Verified: September 2011